Filtered By:
Cancer: Leukemia
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 341 results found since Jan 2013.
Watson arrives in medicine, first stop oncology and chemotherapy recommendations
Today, IBM and MD Anderson announced the development of a prototype of a platform designed to provide treatment recommendations for and help guide the management of oncology patients.
Source: The Palmdoc Chronicles - October 18, 2013 Category: Technology Consultants Authors: Satish Misra, MD Tags: Cancer Decision Support IBM Leukemia MD Anderson Medical/PDA Pathology Watson Oncology Source Type: blogs
The Leukemia & Lymphoma Society's Man of the Year
I don’t dawdle. Just days after my friend nominated me for The Leukemia & Lymphoma Society's 2014 Man of the Year for the National Capital Area Chapter, I accepted. The 10-week campaign will run from April 3 through June 14, 2014. The man (and woman) who generates the most funding for The Leukemia & Lymphoma Society will be crowned champion of the galaxy.
I also don’t make decisions blindly. The Leukemia & Lymphoma Society, founded in 1949, is the world's largest voluntary health organization dedicated to blood cancer. In 2012 it invested $68 million in research. Charity Navigator rates it 3/4 stars o...
Source: I've Still Got Both My Nuts: A True Cancer Blog - October 17, 2013 Category: Cancer Tags: politics Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Rise and shine, everyone, yet another busy day is on the way. And unfortunately, this appears to be a rather rainy one. Nonetheless, our spirits remain sunny. As you may recall, in times like these, we repeat a favorite saying courtesy of the Morning Mayor: 'Every brand new day should be unwrapped like a precious gift.' So while you tug on the ribbon, please join us for a welcome cup of stimulation and a few tidbits to get things going. Hope you accomplish much today and do stay in touch if you hear anything fascinating...
FDA Places Partial Hold On Ariad Cancer Drug Trial Over Side Effects (Reuters)
NIH Enrolls A Dozen Cr...
Source: Pharmalot - October 10, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Harvard Stem Cell Institute publishes initial clinical trial results
Starting with a discovery within zebrafish in 2007, Harvard Stem Cell Institute (HSCI) researchers have published initial results of a Stage Ib human clinical trial of a therapeutic that has the potential to improve the achievements of blood stem cell transplantation. This marks the first time, just nine brief years after Harvard’s major dedication to stem cell biology, that will investigators have carried a breakthrough from the lab bench to the clinic—fulfilling the promise on which HSCI was founded.
The particular Phase 1b safety study, published in the journal Bloodstream , included 12 adult individuals un...
Source: My Irritable Bowel Syndrome Story - October 8, 2013 Category: Other Conditions Authors: Ken Tags: IBS News Source Type: blogs
How much is a month of life worth?
This may be a strange question because prices for anything are determined by markets, and there is no market for a month of life – unless it is your life. Then the question is how much would you pay for that month or, how much would you ask your insurance company or Medicare to pay? I bring this up because of my concern (as well as many other people) about the cost of new cancer drugs. When I first began practicing oncology, it was an exciting time. Many new cancer chemotherapy drugs were being developed, and many of them had major benefits for patients. Also, they were not very expensive. We would be shocked if a course...
Source: Dr.Kattlove's Cancer Blog - October 2, 2013 Category: Oncologists Source Type: blogs
She lit the way in uncertainty
The flow of tears yesterday was both a celebration and a mourning. Yesterday was the ninth anniversary of my first cancer diagnosis. It's a day I'll never forget.In the nine years since I was first diagnosed I've felt tears fall for many reasons...but yesterday was a profound mix of gratitude and guilt. Gratitude for so many things...but a sense of profound sadness triggered by someone else's journey's end.Yesterday I found out that a woman who was a tremendous resource to me during my darkest hours passed away just two weeks ago...from cancer. I didn't even get to say goodbye.Coleen Jones was a classy woman. Her voic...
Source: Life is like a sandwich...enjoy the big bites. - October 2, 2013 Category: Cancer Source Type: blogs
Pharmalot... Pharmalittle... Good Morning
Hello, everyone, and welcome to another working week. Yes, the weekend has come and gone, although we hope you had a chance to relax and refresh yourselves, because that familiar routine of meetings and deadlines and what-not has resumed. This calls, of course, for a cup or two of needed stimulation and, as always, we invite you to join us. Our flavor today is Pumpkin Spice. Meanwhile, here is the usual menu of tidbits to get you going. We hope you have a grand day and drop us a line if you hear something interesting...
FDA Grants Breakthrough Status To Glaxo And Genmab Leukemia Drug (Pharma Times)
Merck Settles False Viox...
Source: Pharmalot - September 16, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
An annual pledge against pinkification
As we approach the month of Pinktober (with 30 days advance notice), it is time for all of us to raise our hands and pledge the following. Please join in.Raise your right hand and repeat after me:I (state your name [and not the Animal House version]) promise that during the month of Pinktober, formerly known as October, I will not arbitrarily purchase pink items or donate to pink causes with out first researching how much actually goes to breast cancer research or screening services. I will first research them using services such as Charity Navigator (www.charitynavigator.org) to ensure they are legitimate.I also prom...
Source: Caroline's Breast Cancer Blog - September 1, 2013 Category: Cancer Tags: pinkification breast cancer pink washing Source Type: blogs
A Human Interest Article on Cancer Immunotherapy
This article is long on the human interest and short on scientific specifics, but is nonetheless an interesting look at the present state and potential for immunotherapies for cancer - one form of the coming generation of targeted cell destruction treatments. Therapies that can cure cancer in a fraction of even late stage patients have moved from the laboratory and into early trials in recent years, a progression that will continue and broaden:
Walt [was] in Philadelphia, where he'd come to be a guinea pig in a test of a new kind of cancer treatment. Leukemia had invaded his bone marrow and spread like a stain through his...
Source: Fight Aging! - August 19, 2013 Category: Health Medicine and Bioethics Commentators Authors: Reason Tags: Daily News Source Type: blogs
Cord blood transplant renews teen’s health – and perspective on life
This article is from Be The Match blog, http://www.bethematchblog.org/2013/06/cord-blood-transplant-renews-teens-health-and-perspective-on-life/
Teenagers are not always known for their sense of perspective. Elizabeth is the exception to the rule.
The source of Elizabeth’s perspective is cancer – specifically, acute lymphocytic leukemia (ALL), first diagnosed when she was 10 years old. Aggressive treatment put the disease in remission after a month, while Elizabeth continued active treatment for two-and-a-half years, pushing through the chemotherapy pills and check-ups while trying to “be a normal kid.” She was app...
Source: Cord Blood News - August 14, 2013 Category: Health Medicine and Bioethics Commentators Authors: joyce at mazelabs.com Tags: Cord Blood medical research stem cells acute lymphocytic leukemia ALL blood cancer cord blood transplant Source Type: blogs
Another T-Cell Advance Against Cancer
The technique of using engineered T cells against cancerous cells may be about to explode ever more than it has already. One of the hardest parts of getting this process scaled up has been the need to extract each patient's own T cells and reprogram them. But in a new report in Nature Biotechnology, a team at Sloan-Kettering shows that they can raise cells of this type from stem cells, which were themselves derived from T lymphocytes from another healthy donor. As The Scientist puts it:
Sadelain’s team isolated T cells from the peripheral blood of a healthy female donor and reprogrammed them into stem cells. The researc...
Source: In the Pipeline - August 14, 2013 Category: Chemists Tags: Cancer Source Type: blogs
Curing Leukemia in Mice With Non-Replicating Viruses
Researchers here demonstrate a way to greatly increase the number of cancer-targeted viruses that can be safely infused into a patient. By disabling the ability of the virus to self-replicate they prevent it from causing dangerous side-effects:
The researchers used a specific method and dose of UV light to transform regular replicating viruses into unique particles that could no longer replicate and spread, but could still enter cancer cells efficiently, kill them and stimulate a strong immune response against the cancer. These particles were able to kill multiple forms of leukemia in the laboratory, including samples tak...
Source: Fight Aging! - August 14, 2013 Category: Health Medicine and Bioethics Commentators Authors: Reason Tags: Daily News Source Type: blogs
Mass Production of Patient-Specific Cancer-Targeting T Cells
Infusions of massive numbers of immune cells is a promising strategy for treating many conditions, as well as being something that would probably benefit any old person as a periodic compensation for the decline in the aging immune system. The technologies to enable this sort of therapy are falling into place:
Scientists have combined the ability to reprogram stem cells into T cells with a recently developed strategy for genetically modifying patients' own T cells to seek and destroy tumors. The result is the capacity to mass-produce in the laboratory an unlimited quantity of cancer-fighting cells that resemble natural T ...
Source: Fight Aging! - August 12, 2013 Category: Health Medicine and Bioethics Commentators Authors: Reason Tags: Daily News Source Type: blogs
More Details on T-Cell Leukemia Therapy
There's an excellent overview at Science of the work of David Porter and Carl June at the University of Pennsylvania on T-cell-based cancer therapy. It turns out that when the dramatic reports came out on their first three patients, the team was out of funding and trying to see if they could get someone interested. They did:
. . .Porter and June weighed their next step. They were itching to test the cell therapy in more people with leukemia, and to do that they needed money that they didn’t have. “We basically decided that we would just publish with three patients,” June says. Getting the word out, he hoped, could s...
Source: In the Pipeline - July 24, 2013 Category: Chemists Tags: Cancer Source Type: blogs
